BAGUERAC Cervical Disc Prosthesis
Spineart USA, Inc. · Decision date Aug 10, 2026
What did the FDA approve?
The FDA approved the BAGUERA® C Cervical Disc Prosthesis from Spineart USA, Inc. on August 10, 2026. The approval covers reconstruction of the disc at one or two contiguous levels from C3-C7 after single-level or two-contiguous-level discectomy in skeletally mature patients with intractable radiculopathy or myelopathy.
Eligible conditions include herniated nucleus pulposus, spondylosis with osteophytes, or visible loss of disc height confirmed by imaging. Patients must have failed at least six weeks of non-operative treatment or have progressive symptoms. The device is implanted via an open anterior approach.
FDA approval order statement
The BAGUERA C Cervical Disc Prosthesis is indicated for use in skeletally mature patients for reconstruction of the disc at one or two contiguous levels from C3-C7 following single-level or two-contiguous-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level or two-contiguous-level abnormality localized to the level of the disc space and manifested by at least one of the following conditions confirmed by radiographic imaging (e.g., X-rays, computed tomography (CT), magnetic resonance imaging (MRI)): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. Patients receiving the BAGUERA C Cervical Disc Prosthesis should have failed at least six weeks of non-operative treatment or have the presence of progressive symptoms (e.g., numbness or tingling) prior to implantation. The BAGUERA C Cervical Disc Prosthesis is implanted via an open anterior approach.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Aug 10, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250042
- Regulatory pathway
- Premarket approval application
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Aug 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250042 received
Application receipt date recorded by FDA.
P250042 · FDA decision
APPR
P250042/S002 · Related supplement
BAGUERAC Cervical Disc Prosthesis
Timeline entries are records held by MedtechLedger for P250042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
Synergy DiscP250028 | Synergy Spine Solutions, Inc. | PMA approval | Feb 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Spineart USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653
Sources and methodology
- Original FDA record: P250042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



